Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

MS portfolio drives growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Idec
 
4Q Revenues: $2.6 billion (+34%)

4Q Earnings: $882.6 million (+93%)

FY Revenues: $9.7 billion (+40%)

FY Earnings: $2.9 billion (+58%)

Comments: TECFIDERA revenues were $916 million, up 130%, consisting of $743 million in U.S. sales and $173 million in sales outside the U.S. AVONEX sales were $736 million in the quarter, down 2%. PLEGRIDY sales were $41.1 million in the quarter. TYSABRI revenues were $484 million, up 13%, consisting of $266 million in U.S. sales and $218 million in sales outside the U.S. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $305 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters